期刊文献+

Effects of Ticagrelor on oxidative stress, coagulation function, platelet function and related factors in patients with coronary artery disease undergoing interventional therapy

在线阅读 下载PDF
导出
摘要 Objective: To explore the effects of Ticagrelor on oxidative stress, coagulation function, platelet function and related factors in patients with coronary artery disease undergoing interventional therapy. Methods: A total of 140 patients with coronary artery disease who underwent percutaneous coronary intervention in our hospital from October 2016 to March 2018 were selected as the study subjects and were divided into control group (70 cases) and observation group (70 cases) by drawing lots. Both groups were treated with symptomatic routine therapy before operation. On this basis, the control group was treated with clopidogrel before operation, and the observation group was treated with Ticagrelor before operation on the basis of routine treatment. The changes of oxidative stress, coagulation index, platelet function and related factors were compared between the two groups before and after treatment. Results: Before treatment, there were no significant differences in oxidative stress factors, coagulation parameters, platelet parameters and related factors factors between the two groups. After treatment, the levels of MDA, MPAR, VEGF and MMP-9 in the two groups were lower than those before treatment, while the levels of SOD, APTT, TT and PT were higher than those before treatment;and the levels of MDA, MPAR, VEGF, MMP-9, APTT and PT in the observation group were significantly lower than those in the control group after treatment, while the levels fo SOD, TT and IPA in the observation group were significantly higher than those in the control group. Conclusions: Ticagrelor can better reduce oxidative stress injury, improve coagulation function and coronary stenosis, and inhibit platelet aggregation in patients with coronary heart disease undergoing PCI than clopidogrel. It has clinical popularization significance.
出处 《Journal of Hainan Medical University》 2019年第6期24-27,共4页 海南医学院学报(英文版)
作者简介 Corresponding author:Xiang-Hong Luo,Department of Anesthesiology,Shiyan Taihe Hospital Affiliated Hospital of Hubei University of Medicine,Shiyan 442000,Hubei,China.E-mail:ms67422@163.com
  • 相关文献

参考文献2

二级参考文献23

  • 1谭大伟,朱平,李小鹰.氯吡格雷抑制血小板功能的两种检测方法比较:血小板聚集实验与血小板膜糖蛋白检测[J].中国组织工程研究与临床康复,2007,11(11):2021-2024. 被引量:11
  • 2Chen ZM, Jiang LX, Chela YP, et al. Addition of elopidogrel to aspi- rin in 45852 patients with acute myocardial infarction: Randomised pla- cebo - control'ted trial [ J ]. Lancet, 2005, 366 ( 9497 ) : 1607 - 1621.
  • 3Wallentin L, Becket RC, Budaj A, et 81. Tieagrelor versus clopi- dogrel in patients with acute.coronary syndromes [ J]. N Engl J Med, 2009, 361 (11): 1045-57.
  • 4Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopy- ridines clinical detection of coronary stent thrombosis bymonitoring of vas- odilator - stimulated phosphoprotein phosphorylation [J]. Catheter Car- diovasc Interv, 2003, 59 (3) : 295 - 302.
  • 5Nguyen TA, Diodati JG, Pharand C. Resistance to elopidogrel a review of the evidence [J]. J Am Call Cardiol, 2005, 45 (8): 1157- 1164.
  • 6Collet JP, Hulot JS, Anzaha G, et al. High doses of clopidogrel to o-vereome genetic resistance : the randomized crossover CLOVIS - 2 ( Clo- pidogrel and Response Variability Investigation Study 2 ) [ J ]. JACC Cardiovasc Inrerv, 2011, 4 (4) : 392-402.
  • 7FDA drug safety communieation: Reduced dffectiveness of Plavix ( clo- pidogrel) in patients who are poor metabolizers of the drug [ EB/OL]. http: //www. fda. gov/Drugs/DrugSafty/Postmarket Drug Safety Infor- mation for Patientsand Providers/uem203888. htm.
  • 8Geisler T, Langer H, Wydymus M, et al. Low response to elopidogrel is associated with cardiovascular outcome after coronary stent implantation [J]. Eur Heart J, 2006, 27 (20) : 2420-2425.
  • 9Boneno L, Tantry US, Mareucci R, et al. Consensus and future direc- tions on the definition of high on - clopidogrel platelet reactivity to adeno- sine diphosphate [J]. J Am Coil Cardiol, 2010, 56:919 -933.
  • 10Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pre- treatment platelet reactivity [ J ]. Circulation, 2003, 107 ( 23 ) : 2908 - 2913.

共引文献65

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部